Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents: Commentary

Tom Huizinga; Peter Nigrovic; Eric Ruderman; Hendrik Schulze-Koops

Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents: Commentary

Tom Huizinga^*, Peter Nigrovic, Eric Ruderman, Hendrik Schulze-Koops

^*Corresponding author for this work

Medicine, Rheumatology Division

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	143-144
Number of pages	2
Journal	International Journal of Advances in Rheumatology
Volume	9
Issue number	4
State	Published - 2011

ASJC Scopus subject areas

Rheumatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Huizinga, T., Nigrovic, P., Ruderman, E., & Schulze-Koops, H. (2011). Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents: Commentary. International Journal of Advances in Rheumatology, 9(4), 143-144.

Huizinga, Tom ; Nigrovic, Peter ; Ruderman, Eric et al. / Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents : Commentary. In: International Journal of Advances in Rheumatology. 2011 ; Vol. 9, No. 4. pp. 143-144.

@article{e04c7fb7941f4b0fb16075e553bbbdac,

title = "Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents: Commentary",

author = "Tom Huizinga and Peter Nigrovic and Eric Ruderman and Hendrik Schulze-Koops",

year = "2011",

language = "English (US)",

volume = "9",

pages = "143--144",

journal = "International Journal of Advances in Rheumatology",

issn = "1478-856X",

publisher = "Remedica Medical Education and Publishing Ltd",

number = "4",

}

Huizinga, T, Nigrovic, P, Ruderman, E & Schulze-Koops, H 2011, 'Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents: Commentary', International Journal of Advances in Rheumatology, vol. 9, no. 4, pp. 143-144.

Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents: Commentary. / Huizinga, Tom; Nigrovic, Peter; Ruderman, Eric et al.
In: International Journal of Advances in Rheumatology, Vol. 9, No. 4, 2011, p. 143-144.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents

T2 - Commentary

AU - Huizinga, Tom

AU - Nigrovic, Peter

AU - Ruderman, Eric

AU - Schulze-Koops, Hendrik

PY - 2011

Y1 - 2011

UR - http://www.scopus.com/inward/record.url?scp=84863975497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863975497&partnerID=8YFLogxK

M3 - Comment/debate

AN - SCOPUS:84863975497

SN - 1478-856X

VL - 9

SP - 143

EP - 144

JO - International Journal of Advances in Rheumatology

JF - International Journal of Advances in Rheumatology

IS - 4

ER -

Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents: Commentary

ASJC Scopus subject areas

UN SDGs

Other files and links

Cite this